ライフサイエンスコーパス: chloromethyl

1 -methoxy-, 2-methoxy-, 4,4'-dimethyl-, and 4-chloromethyl-).

2 2-Chloromethyl and 3-chloromethyl-1,6-methano[10]annulene systems solvolyze i

3 cleaved DNA strand is readily alkylated by 7-chloromethyl 10,11-methylenedioxy CPT; (ii) CPT generall

4 We demonstrate that 7-CM-EDO-CPT (7-chloromethyl-10,11-ethylenedioxy-camptothecin) also indu

5 alkylating camptothecin (CPT) derivative, 7-chloromethyl-10,11-methylenedioxy-camptothecin (7-CM-MDO

6 Alkylation of the top1 cleavage complex by 7-chloromethyl-10,11-methylenedioxycamptothecin (7-ClMe-MD

7 ethylenedioxycamptothecin, 20(S)-glycinate-7-chloromethyl-10,11-methylenedioxycamptothecin, and CPT-1

8 rified beta-tubulin that had reacted with 3-(chloromethyl-[14C] Carbonyl)-3- demethylthiocolchicine (

9 This beta-tubulin that had reacted with 3-(chloromethyl-[14C]carbonyl)- 3-demethythiocolchicine ([1

10 2S,5R)-(-)-menthoxymethylimidazole as amine, chloromethyl (1R,2S,5R)-(-)-menthyl ether as quaternizat

11 In the second method, imidazole, chloromethyl (1R,2S,5R)-(-)-menthyl ether, and DMF are u

12 Reaction of Meldrum's acid with 3,4-bis(chloromethyl)-2,5-dimethylthiophene (1) or 3,4-bis(bromo

13 ch mel were first pre-labeled with 5-(and-6)-chloromethyl-2',7'-dichlorodihydro-fluorescein diacetate

14 microscopy with the fluorescent probe 5',6'-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate

15 of ROS in HRECs was examined using 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate

16 ectively, as derived from the dyes 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate

17 en species were assessed using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate

18 essed by measuring fluorescence of 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate,

19 was detected by the oxidation of 5- (and -6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate,

20 S levels were measured by using the 5- and 6-chloromethyl-2',7'-dichlorodihydrofluorescence diacetate

21 by using dihydroethidium assay and 5-(and 6)-chloromethyl-2',7'-dichlorodihydrofluorescence diacetate

22 ted with the fluorigenic substrate 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescin diacetate,

23 Among tested compounds 4'-chloromethyl-2'-deoxy-2'-fluorocytidine (2c) exhibited t

24 ion of methylenebisacetamide with 3-chloro-2-chloromethyl-2-propene to provide 5-exomethylene-1, 3-di

25 n the pseudo-first-order formation of (Z)-2-(chloromethyl)-3-(2-hydroxyphenyl)-2-propenoic acid.

26 actions of the bifunctional allylstannane 2-(chloromethyl)-3-(tributylstannyl)propene with aldehydes

27 ntraction to (2S,3R,4S,5S,1'R)-N(1)-benzyl-2-chloromethyl-3-benzyloxy-4,5-epoxypiperidine followed by

28 give the 4-(chloromethyl)benzoyl ester of 4-(chloromethyl)-4'-hydroxybenzophenone followed by reactio

29 the presence of an electrophilic reagent, 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane

30 coupling of the triamines 4a-d with 2, 6-bis(chloromethyl)-4-methylphenol 5 and results in the format

31 monocarbonyl compounds, with Selectfluor (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane b

32 ul analogues (MXY, in general): (3-chloro-4-(chloromethyl)-5-hydroxy-2(5H)-furanone -CMCF- and 3-chlo

33 y, a conjugate molecule [polyamide 1-CBI (1-(chloromethyl)-5-hydroxyl-1,2-dihydro-3H-benz[e]indole) c

34 fords a conjugate 1-CBI (polyamide 1-CBI (1-(chloromethyl)-5-hydroxyl-1,2-dihydro-3H-benz[e]indole) c

35 6-Chloromethyl-6-methylfulvene, also a primary, allylic ha

36 lfonyl-THIQ (R-13) and both enantiomers of 3-chloromethyl-7-nitro-THIQ (R- and S-30) are the most sel

37 of 3-fluoromethyl-, 3-hydroxymethyl-, and 3-chloromethyl-7-substituted-1,2,3,4-tetrahydroisoquinolin

38 rhomboid protease inhibitor N-p-Tosyl-l-Phe chloromethyl abolishes the induction of AOX1a upon antim

39 Chloromethyl addition was achieved under both the tin-fr

40 Undisclosed chloromethyl alkanoates (chloromethyl propanoate, pentan

41 chloromethylcarbinols for the preparation of chloromethyl-alpha-diketones, trichloromethylated dihydr

42 2-Chloromethyl and 3-chloromethyl-1,6-methano[10]annulene

43 Iodomethyl-, chloromethyl-, and fluoromethyldimethylsulfonium salts,

44 sulfonium ylide 4, and sulfonyl-substituted chloromethyl anion 5.

45 tion of 3-methylbenzoate affording methyl 3-(chloromethyl)benzoate, which is an important building bl

46 y a synthetic route involving reaction of 4-(chloromethyl)benzoic anhydride with phenol in polyphosph

47 phenol in polyphosphoric acid to give the 4-(chloromethyl)benzoyl ester of 4-(chloromethyl)-4'-hydrox

48 with a fluorescent vital dye [(5-(and-6)-((4-chloromethyl)benzoyl)amino)tetramethylrhodamine], which

49 The classical antifolate 7 utilized 4-(chloromethyl)benzoyl-l-glutamic acid diethyl ester (17)

50 e at m1 receptors, approximately 3-fold by N-chloromethyl brucine at m3 receptors, and approximately

51 he subtype-selective allosteric effects of N-chloromethyl brucine on M2 and M3 receptors were shown t

52 The enhancing action of N-chloromethyl brucine on neurogenically released ACh bind

53 Neutral cooperativity of N-chloromethyl brucine with ACh on M4 receptor function wa

54 tudies, it has been reported that brucine, N-chloromethyl brucine, and brucine N-oxide increased the

55 ric site that binds strychnine (and probably chloromethyl brucine, another allosteric enhancer) there

56 plays selectivity for the carbonyl carbon of chloromethyl carbonyl electrophiles.

57 actions conducted at 0 degrees C afforded 2-(chloromethyl)cinnamic acid derivatives as the major prod

58 -2) with the fluorogenic substrate 7-amino-4-chloromethyl coumarin (CMAC).

59 ogenic rGSTT2-2-specific substrate 7-amino-4-chloromethyl coumarin led to the isolation of active var

60 ed in refluxing acetic acid, however, the 3-(chloromethyl)coumarin derivatives are the sole products.

61 the major products and the corresponding 3-(chloromethyl)coumarin derivatives as the minor products.

62 The chloromethyl derivative 3 readily decomposes on warming

63 fluorometrically using propidium iodide and chloromethyl dihydrodichlorofluorescein, respectively.

64 5ClCH2(CH3)2SiOSi(CH3)2+ formed from 1,3-bis(chloromethyl)disiloxane upon an F-SAM surface, (iv) surf

65 synthetic methodology is efficient and uses chloromethyl ethers derived from the chirons diethyl (3S

66 wed by a Wittig reaction with 2,4-diamino-5-(chloromethyl)furo[2,3-d]pyrimidine (6), catalytic hydrog

67 sized by a Wittig reaction of 2,4-diamino-5-(chloromethyl)furo[2,3-d]pyrimidine with ethyl 4-acetylbe

68 nucleophilic displacement of 2,4-diamino-5-(chloromethyl)furo[2,3-d]pyrimidine(2) with the appropria

69 highly reactive, genotoxic intermediate, S-(chloromethyl)glutathione (GS-CH(2)Cl).

70 oate (14), which was elaborated to the alpha-chloromethyl ketone (8) followed by condensation with 2,

71 ltransferase (LRAT) with 10-N-acetamidodecyl chloromethyl ketone (AcDCMK) or cellular retinol-binding

72 The hemiketal hydroxyl groups in chloromethyl ketone (cmk) complexes of trypsin and chymo

73 hloride (AEBSF) and decanoyl-Arg-Arg-Leu-Leu-chloromethyl ketone (dec-RRLL-cmk), inhibitors of SKI-1

74 ing the membrane-permeable synthetic peptide chloromethyl ketone (decanoyl-RVKR-CMK) blocked regulate

75 the active site inhibitor dansyl-Glu-Gly-Arg-chloromethyl ketone (DEGR-CMK) in a slow reaction.

76 he synthesis of paclitaxel (PTX)-Phe-Phe-Arg-chloromethyl ketone (FFR-ck), followed by coupling with

77 The optimized inhibitor peptide dPhe-Pro-Arg chloromethyl ketone (PPACK) was used to simulate the sub

78 y treatment of the enzyme with D-Phe-Pro-Arg-chloromethyl ketone (PPACK), a reagent that irreversibly

79 ride (PMSF) (100%), N-alpha-p-tosyl-l-lysine chloromethyl ketone (TLCK) (85.4%), benzamidine (80.2%),

80 ted by the protease inhibitor tosyl-l-lysine chloromethyl ketone (TLCK) (P < 0.05).

81 ther treatment with N alpha-p-tosyl-L-lysine chloromethyl ketone (TLCK) and dithiothreitol was perfor

82 lso was inhibited by Nalpha-p-tosyl-L-lysine chloromethyl ketone (TLCK) and, to a lesser extent, H-D-

83 e protease inhibitor Nalpha-p-tosyl-L-lysine chloromethyl ketone (TLCK) blocked its effects on cultur

84 inhibitors ZnCl2 and Nalpha-p-tosyl-l-lysine chloromethyl ketone (TLCK) exhibited dose-dependent inhi

85 hloromethyl ketone (TPCK) and tosyl-L-lysine chloromethyl ketone (TLCK) modified the HPV type 18 E7 p

86 proteasome inhibitor Nalpha-p-tosyl-L-lysine chloromethyl ketone (TLCK) or by infection with rAd-Ikap

87 revented apoptosis, whereas N-tosyl-L-lysine chloromethyl ketone (TLCK), Ac-Leu-Leu-L-norleucinal, Ac

88 protease inhibitor, Nalpha-P-tosyl-L-lysine chloromethyl ketone (TLCK), and a proteasome complex (26

89 ly blocked apoptosis, but N-p-tosyl-L-lysine chloromethyl ketone (TLCK), another serine protease inhi

90 serine protease inhibitor, N-tosyl-L-lysine chloromethyl ketone (TLCK), dramatically enhances Fas-me

91 seen with active and Nalpha-p-tosyl-L-lysine chloromethyl ketone (TLCK)-inactivated HRgpA, indicating

92 e chloromethyl ketone (TPCK) and tosyllysine chloromethyl ketone (TLCK).

93 and by exposure to N alpha-p-tosyl-L-lysine chloromethyl ketone (TLCK).

94 rtially inhibited by N-tosyl-l-phenylalanine chloromethyl ketone (TPCK) (10.3%), ethylendiaminetetraa

95 serine protease inhibitors, N-tosyl-L-phenyl chloromethyl ketone (TPCK) and 3,4-dichloroisocoumarin (

96 ne protease inhibitors tosyl-L-phenylalanine chloromethyl ketone (TPCK) and tosyl-L-lysine chlorometh

97 erine protease inhibitors tosylphenylalanine chloromethyl ketone (TPCK) and tosyllysine chloromethyl

98 tease inhibitor L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK) did not inhibit the sensitiza

99 e protease inhibitor N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) effectively blocked apoptosis

100 tive effects of N-alpha-tosyl-l-phenylalanyl chloromethyl ketone (TPCK) have been known for more than

101 ease inhibitor N-alpha-tosyl-L-phenylalanine chloromethyl ketone (TPCK) prevents UV activation of HIV

102 hymotryptic inhibitor N-tosyl-L-phenylalanyl-chloromethyl ketone (TPCK) suppressed DNA fragmentation

103 WEH1 231 cells with N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), a protease inhibitor which p

104 B inhibitor, or l-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK), a serine protease inhibitor

105 e infection to l-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK), a serine-cysteine protease i

106 itors, dexamethasone and n-tosylphenyalanine chloromethyl ketone (TPCK), abolishes constitutive RelA

107 were inactivated by N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), an inhibitor of chymotrypsin

108 NF-kappa B, SN50 and N-tosyl-l-phenylalanine chloromethyl ketone (TPCK), blocks TNF-induced Akt activ

109 e protease inhibitor N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), which blocks the normally ra

110 e protease inhibitor N-Tosyl-L-Phenylalanine Chloromethyl Ketone (TPCK).

111 ine protease inhibitor tosyl-L-phenylalanine chloromethyl ketone (TPCK).

112 to a lesser extent, H-D-Tyr-L-Pro-L-arginyl chloromethyl ketone (YPRCK) and was relatively insensiti

113 roteinase inhibitor N-alpha-p-tosyl-L-lysine chloromethyl ketone and also by a caspase inhibitor.

114 The factor Xa inhibitor DEGR-chloromethyl ketone and an antibody to factor X inhibite

115 ysis are inhibited by acetyl-Tyr-Val-Ala-Asp chloromethyl ketone and CrmA, specific inhibitors of ICE

116 protease inhibitors N-tosyl-L -phenylalanine chloromethyl ketone and N-acetyl-L -leucinyl-L -leucinyl

117 hrough inhibition studies with both peptidyl chloromethyl ketone and organophosphate inhibitors.

118 was corroborated by inhibition studies with chloromethyl ketone and organophosphonate inhibitors.

119 ors of this pathway, N-tosyl-l-phenylalanine chloromethyl ketone and pyrrolidine dithiocarbamate, abr

120 aB inhibitors, e.g., N-tosyl-l-phenylalanine chloromethyl ketone and SN50, a result that is consisten

121 licated in apoptosis, only tosylphenylalanyl chloromethyl ketone and the nuclear scaffold protease in

122 zyme activity in the presence of N-p-tosyl-L-chloromethyl ketone and the partial inhibition of enzyme

123 tone, ALLN, and Nalpha-tosyl-L-phenylalanine chloromethyl ketone and was relatively unaffected by lac

124 proteasome inhibitor N-tosyl-L-phenylalanine chloromethyl ketone blocked expression of TF mRNA and ac

125 caspase-1 activity by acetyl-Tyr-Val-Ala-Asp-chloromethyl ketone blocks macrophage cytotoxicity, and

126 The co-crystal structure revealed the chloromethyl ketone bound to the N-terminal nucleophile

127 e and to the inhibitor-derived oxyanion in a chloromethyl ketone complex, observations that strongly

128 onyl)-L-Leu]-agmatine (E-64) and tosyl-L-Lys chloromethyl ketone did not inhibit PEPase activity.

129 stabilization of FXa(I16L) with Glu-Gly-Arg-chloromethyl ketone fully rescued FVa binding.

130 onvertase inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone had greater versican-cleaving activi

131 sence or absence of decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone in COS-7 cells expressing Phex and F

132 transitions, we designed a pantetheine-like chloromethyl ketone inactivator and co-crystallized it w

133 hibitor of trypsin, N-alpha-p-tosyl-L-lysine chloromethyl ketone inhibited 99.67% activity.

134 Tosyl-lysyl chloromethyl ketone inhibited the trypsin-like protease

135 D-Phe-Pro-Arg-chloromethyl ketone inhibition at the thrombin active si

136 was blocked by active site-directed peptide chloromethyl ketone inhibitors; (ii) the kinetics of com

137 zothiazole group linked to the D-Phe-Pro-Arg chloromethyl ketone motif.

138 labeling with dansyl-glutamyl-glycyl-arginyl chloromethyl ketone or immunoblot analysis showed no det

139 n S and a triazole inhibitor incorporating a chloromethyl ketone pharmacophore guided the design of t

140 midine-FVIIa/sTF crystals with d-Phe-Pro-Arg-chloromethyl ketone results in benzamidine displacement,

141 The PC inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone significantly suppressed FLAG-pro-GX

142 sing Xa modified with a fluorescent peptidyl chloromethyl ketone to irreversibly occlude the active s

143 nding of the covalent inhibitor dPhe-Pro-Arg chloromethyl ketone to the active site serine, as well a

144 ed by 1 mM N-methoxysuccinyl-Ala-Ala-Pro-Val chloromethyl ketone when it was present during activatio

145 ase inhibitors TLCK (Nalpha-p-tosyl-l-lysine chloromethyl ketone) and E-64 [l-trans-epoxysuccinyl-leu

146 s inhibited by TLCK (Nalpha-p-tosyl-L-lysine chloromethyl ketone) and iodoacetamide.

147 inactivated by TLCK (Nalpha-p-tosyl-L-lysine chloromethyl ketone) and proteinase K treatment.

148 ffold multicatalytic proteinase (Ala-Pro-Phe chloromethyl ketone) block the degradation of lamin B1 t

149 -kappaB inhibitor (N-p-Tosyl-L-phenylalanine chloromethyl ketone) that restored PGC-1alpha recovery a

150 nhibited by TPCK (tolylsullonyl phenylalanyl chloromethyl ketone), PMSF (phenylmethylsulfonyl fluorid

151 ase inhibitor TLCK (N alpha-p-tosyl-L-lysine chloromethyl ketone), pronase, or proteinase K, suggesti

152 tion of phenylalanine-phenylalanine-arginine chloromethyl ketone, (FFRck) followed by coupling with t

153 Tyr-Val-Ala-Asp-chloromethyl ketone, a caspase-1 inhibitor, prevented AT

154 more specifically N-p-tosyl-L-phenylalanine chloromethyl ketone, a chymotrypsin-like proteinase inhi

155 ed by N-acetyltyrosinylvalinylalanylaspartyl chloromethyl ketone, a peptide inhibitor of interleukin-

156 ccinyl-alanine-alanine-proline-valine (AAPV) chloromethyl ketone, a specific neutrophil elastase inhi

157 l prothrombin derivatives with D-Phe-Pro-Arg-chloromethyl ketone, analogous to irreversible binding o

158 loromethyl ketone, N(alpha)-p-tosyl-L-lysine chloromethyl ketone, and N-(N(alpha)-benzyloxycarbonylph

159 could be blocked by N-tosyl-L-phenylalanine chloromethyl ketone, calpeptin, and pyrrolidine dithioca

160 arbonyl-glycine-leucine-phenylalanine (ZGLF) chloromethyl ketone, had no effect.

161 irudin and D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone, indicating that the effect of c7E3

162 itor of serine proteases, Na-p-Tosyl-L-lysyl-chloromethyl ketone, inhibited radiation-induced apoptos

163 socoumarin, N(alpha)-p-tosyl-L-phenylalanine chloromethyl ketone, N(alpha)-p-tosyl-L-lysine chloromet

164 se inhibitor N alpha-L-tosyl-L-phenylalanine chloromethyl ketone, suggesting that a nuclear factor-ka

165 tick-anticoagulant-peptide and D-Glu-Gly-Arg-chloromethyl ketone, the latter two being specific inhib

166 proteinase inhibitor and dec-Arg-Val-Lys-Arg-chloromethyl ketone, two specific furin inhibitors, bloc

167 interactions, we crystallized d-Phe-Pro-Arg-chloromethyl ketone-inhibited human thrombin in complex

168 ts by an endogenous decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone-sensitive furin-type convertase.

169 luoride and N(alpha)-p-tosyl-L-phenylalanine chloromethyl ketone.

170 in the presence of N-alpha-p-tosyl-L-lysine chloromethyl ketone.

171 unaffected by lactacystin and N-tosyl lysyl chloromethyl ketone.

172 , tick anticoagulant peptide, or Glu-Gly-Arg-chloromethyl ketone.

173 tor, CrmA, and N-alpha-tosyl-L-phenylalanine chloromethyl ketone.

174 bitor, or d-phenylalanyl-l-prolyl-l-arginine chloromethyl ketone.

175 toichiometrically with the thioester peptide chloromethyl ketone.

176 nt adduct of Chtr with N-p-tosylphenylalanyl chloromethyl ketone.

177 on with phenylalanine-phenylalanine-arginine-chloromethyl ketone.

178 cubation with a caspase-3 inhibitor (Ac-DEVD-chloromethyl-ketone) further attenuated the ultraviolet

179 synthetic inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethyl-ketone, CMK, showed a significant decrease

180 to the active site inhibitor H-d-Phe-Pro-Arg-chloromethyl-ketone, document the conformational changes

181 f sodium tolylsulfinate with bromomethyl- or chloromethyl ketones generates beta-keto sulfones.

182 Biotin derivatives of peptide chloromethyl ketones have ideal properties for specific

183 2-chloroacetamidine is analogous to that of chloromethyl ketones, a set of inhibitors that have foun

184 bitors may be applicable to other tripeptide chloromethyl ketones, and the reagents can be employed f

185 the PBPs were synthesized, including peptide chloromethyl ketones, trifluoromethyl ketones, aldehydes

186 combined with the electron affinity of the 5-chloromethyl-m-xylylene biradical (1.120 +/- 0.059 eV) t

187 benzene, which was generated by CID of the 5-chloromethyl-m-xylylene ion.

188 al(k)Val units were prepared and attached to chloromethyl Merrifield resin via the carboxy terminal.

189 highest affinity and THIQs containing the 3-chloromethyl moiety the least.

190 nversion to a chloride gave 5-substituted 3-(chloromethyl)- or 3-(2-chloroethyl)pyrazoles.

191 nt of acetyl chloride, benzoyl chloride, and chloromethyl oxalate to the 3-position of 4-, 5-, 6-, or

192 ion between tert-butoxycarbonyl alaninal and chloromethyl phenyl sulfone afforded chlorohydrins, whic

193 s to organelles that double-label with 8-(4'-chloromethyl) phenyl-2,3,5,6,11,12,14,15-octahydro-1H,4H

194 hanol, alpha-ionone, 3-methyl-1-indanone, o-(chloromethyl)phenyl sulfoxide, o-(bromomethyl)phenyl sul

195 lf-assembling a densely bonded monolayer of (chloromethyl)-phenylethyltrichlorosilane (CMPES).

196 a novel derivatizing reagent, di-tert-butyl chloromethyl phosphate, resulting in formation of the qu

197 oxides bearing alkyl, alkenyl, aryl, alkoxy, chloromethyl, phthalimido, and acetal functional groups.

198 2,2-bis(chloromethyl)propane-1,3-diyltetrakis(2-chloroethyl) bis

199 hexyl) adipate (DEHA)), and one FR (2,2-bis (chloromethyl)-propane-1,3-diyltetrakis(2-chloroethyl) bi

200 Undisclosed chloromethyl alkanoates (chloromethyl propanoate, pentanoate, and octanoate) were

201 nucleophilic displacement of 2,6-diamino-8-(chloromethyl)purine with the appropriate anilines or 2-n

202 tetramethylindo carbocyanine perchlorate, or chloromethyl tetramethylrhodamine.

203 ese 3-fluoromethyl-, 3-hydroxymethyl-, and 3-chloromethyl-THIQs indicates that all of the 3-substitut

204 ese 3-fluoromethyl-, 3-hydroxymethyl-, and 3-chloromethyl-THIQs.

205 Flow cytometry experiments using chloromethyl-X-rosamine and Indo-1 revealed FimH-depende